Article Versions Notes

Ito S, Hamada T, Nakagawa M, Ichinohe T, Nukariya H, Endo T, Kurihara K, Takeuchi Y, Otake S, Takahashi H, et al. Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy. Hematology Reports. 2025; 17(6):57. https://doi.org/10.3390/hematolrep17060057

Ito, Shun, Takashi Hamada, Masaru Nakagawa, Takashi Ichinohe, Hironao Nukariya, Toshihide Endo, Kazuya Kurihara, Yuichi Takeuchi, Shimon Otake, Hiromichi Takahashi, and et al. 2025. "Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy" Hematology Reports 17, no. 6: 57. https://doi.org/10.3390/hematolrep17060057

Ito, S., Hamada, T., Nakagawa, M., Ichinohe, T., Nukariya, H., Endo, T., Kurihara, K., Takeuchi, Y., Otake, S., Takahashi, H., Nakamura, H., & Miura, K. (2025). Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy. Hematology Reports, 17(6), 57. https://doi.org/10.3390/hematolrep17060057